title: [Research on progress and prospect of kinase S6K1].
abstract: Obesity is a prevalent metabolic disorder, which seriously affects human health and has become the world's public health problem. Kinase S6K1, an important downstream effector of mammalian target of rapamycin (mTOR), influences specific pathological responses, including obesity, type 2 diabetes and cancer. Presently, S6K1 has become an attractive therapeutic target in the treatment of these disorders. Here, the functions of kinase S6K1, its molecular regulation mechanisms, related pathogenesis of disease and relevant small molecular inhibitors are reviewed. Finally, the prospect of research toward S6K1 is expected as well.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Junyu
authors.initials: J
authors.lastname: Liang
authors.forename: Ji
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2; D006801:Humans; D009369:Neoplasms; D009765:Obesity; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000378:metabolism*; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism
chemical_list: C546842:MTOR protein, human; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases; C448901:ribosomal protein S6 kinase, 70kD, polypeptide 1